The importance of early antihypertensive efficacy: The role of angiotensin II receptor blocker therapy

Journal of Human Hypertension

Volumn 20, Issue 3, 2006, Pages 169-175

  Basile, J N ^a   Chrysant, S ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin II type 1 receptor blockers; Blood pressure goal rates; Calcium channel blockers; Early antihypertensive efficacy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS;

EID: 33745915553     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001972     Document Type: Article

References (38)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
2. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
4. World Health Organization. World Health Report 2002: reducing risks promoting healthy life. 2002 cited; Available from: http://www.who.int/whr/2002.
5. Nesbitt SD, Julius S. Prehypertension: a possible target for antihypertensive medication. Curr Hypertens Rep 2000; 2: 356-361.
6. Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens Suppl 1999; 17: S3-S7.
7. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
8. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
9. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, doubleblind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861-866.
10. Cappuccio FP, Markandu ND, Singer DR, Buckley MG, Miller MA, Sagnella GA et al. A double-blind crossover study of the effect of concomitant diuretic therapy in hypertensive patients treated with amlodipine. Am J Hypertens 1991; 4: 297-302.
11. Mann J, Julius S. The valsartan antihypertensive longterm use evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7: 176-183.
12. Lindholm LH. Valsartan treatment of hypertension - does VALUE add value? Lancet 2004; 363: 2010-2011.
13. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051.
14. Bloch MJ, Basile J. Analysis of recent papers in hypertension: there is value in early blood pressure reduction. J Clin Hypertens (Greenwich) 2004; 6: 598-600.
15. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
16. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-1180.
17. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V et al. The study on cognition and prognosis in the elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press 2005; 14: 31-37.
18. Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847-857.
19. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S et al. VALUE trial: long-term blood pressure trends in 13, 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-548.
20. Bakris GL, Weir MR. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003; 5: 202-209.
21. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan study investigators. Am J Hypertens 1998; 11: 445-453.
22. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12: 414-417.
23. Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-664.
24. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425-432.
25. Chrysant SG, Wang A. Olmesartan medoxomil lowers blood pressure as rapidly as amlodipine besylate in patients with mild to moderate hypertension: results of a randomized, double-blind, placebo-controlled study [abstract]. Am J Hypertens 2004; 17: 102A Abstract P-188. Data on file. Sankyo Pharma, Inc.: Parsippany, NJ, 2003.
26. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel JM. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-291, 318.
27. The sixth report of the Joint National Committee on prevention, detection, evaluation, treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
28. Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc) 2004; 40: 791-801.
29. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43: 1343-1347.
30. Drexler H. Factors involved in the maintenance of endothelial function. Am J Cardiol 1998; 82: 3S-4S.
31. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A; discussion 10A.
32. Slaninka-Miceska M, Bogdanska J, Korneti P, Kostova E, Jovanoska E, Petrov S. Effect of angiotensin II type 1 (AT1) receptor antagonist on the endothelial dysfunction in spontaneously hypertensive rats in correlation with the nitric oxide system. Bratisl Lek Listy 2003; 104: 342-346.
33. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long-term irbesartan treatment on endotheliumdependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003; 60: 191-196.
34. Mogensen CE. The reno-protective role of AT(1)- receptor blockers. J Hum Hypertens 2002; 16(Suppl 3): S52-S58.
35. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-496.
36. Jokisalo E, Enlund H, Halonen P, Takala J, Kumpusalo E. Factors related to poor control of blood pressure with antihypertensive drug therapy. Blood Press 2003; 12: 49-55.
37. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-1963.
38. Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413-420.